

### AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

#### Listing of Claims:

1. (Currently amended) A method of assessing a risk of a human patient for developing an adverse drug reaction in response to a drug, comprising

detecting the presence of an HLA-B\*1502 allele in a sample obtained from the patient, and

correlating the presence of the HLA-B\*1502 allele in the sample with, which is indicative of an increased risk for an adverse drug reaction in the patient in response to the drug, wherein the adverse drug reaction is ~~selected from the group consisting of~~ Stevens-Johnson syndrome ~~[[and]]~~ or toxic epidermal necrolysis, and wherein the drug is a carbamazepine.

2-7. (Canceled)

8. (Currently Amended) The method of claim 1 wherein the presence of the allele is determined by using an oligonucleotide that specifically hybridizes to ~~with the~~ nucleic acid coding for the allele.

9. (Currently Amended) The method of claim 1 wherein the presence of the allele is determined by using DNA prepared from ~~[[the]]~~ peripheral blood of the patient.

10. (Currently Amended) The method of claim 1 wherein the presence of the allele is determined by using RNA, protein, cells or sera prepared from ~~[[the]]~~ peripheral blood of the patient.

Applicant(s) : Yuan-Tsong Chen, et al.  
Serial No. : 10/705,245  
Filed : November 10, 2003  
Page : 3 of 7

Attorney Docket No.: 70003-003001  
Client Ref. No.: 12A-920716

11-25. (Cancelled)

26. (New) The method of claim 1, wherein the adverse drug reaction is Stevens-Johnson syndrome.

27. (New) The method of claim 1, wherein the adverse drug reaction is toxic epidermal necrolysis.